OpportunityTitle: Limited Competition: Clinical Trials in Organ Transplantation in Children (CTOT-C): Mechanistic Ancillary Studies (U01)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description: This Funding Opportunity Announcement (FOA) solicits applications from currently funded Program Directors/Principal Investigators, Mechanistic Subcommittee members, core laboratory leaders and clinical site leaders in the &quot;Clinical Trials in Organ Transplantation in Children (CTOT-C)&quot; Program to support the conduct of studies of immune mechanisms using samples and clinical data collected from pediatric solid organ transplant recipients obtained in (a) ongoing or completed CTOT-C clinical studies, or (b) from other clinical trials in which the samples and data were collected with a demonstrably similar level of investigational rigor. Research supported under this FOA will focus on understanding graft dysfunction and/or loss and immune-mediated morbidity and mortality in pediatric transplant recipients. This FOA will leverage the samples and data gathered from CTOT-C&apos;s unique cohort of well-characterized patients, as well as the consortium infrastructure to carry out timely hypothesis-driven mechanistic studies. Successful ancillary mechanistic investigations will enhance the value of ongoing and completed CTOT-C projects, improve the research community&apos;s understanding of pediatric transplantation, and contribute to the identification of novel and robust surrogate endpoints for future interventional trials and/or novel therapeutic targets and biomarkers for diagnosis, treatment, and disease monitoring.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;